Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government's Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.
Pfizer and BioNTech announce agreement with the United Kingdom for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.
GSK and CureVac announce strategic mRNA technology collaboration
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK's existing mRNA capabilities with CureVac’s integrated mRNA platform.
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
- Details
- Category: AstraZeneca
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years. It assessed a single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY.
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
- Details
- Category: Novartis
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 - a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can lead to death in some people, putting immense strain on fragile healthcare systems.
Pfizer and BioNTech granted FDA Fast Track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA).
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).
More Pharma News ...
- GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
- Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection
- Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
- Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
- Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
- GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
- Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges